📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 16:54
6 analysed today
FollowTelegram
6
Today
149,957
All-time analysed
42,989
Positive
6,669
Negative
91,589
Neutral
8,642
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1 announcement match the current filters (relevance ≥ 5).
Shree Pacetronix Q1 PAT up 13.4% YoY to ₹0.76 Cr; Revenue dips 8.2%
Shree Pacetronix reported a mixed Q1 FY27 with standalone revenue declining 8.2% YoY to ₹4.90 Cr. Despite the top-line dip, Profit After Tax (PAT) grew 13.4% YoY to ₹0.76 Cr, primarily driven by a 78.7% reduction in finance costs. Sequentially, performance was weaker with revenue and PAT falling 8.7% and 21.6% respectively compared to Mar 2026. A significant highlight is the increase in promoter holding to 36.44% from 31.7% in the previous quarter.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results showing a contraction in revenue but improved bottom-line efficiency due to lower interest expenses and cost control.
Why it mattersFor a micro-cap company with a ₹50 Cr market cap, maintaining double-digit PAT growth and increasing promoter skin-in-the-game are positive signals, though the revenue decline warrants caution regarding market share.
Revenue (Q1 FY27): ₹4.90 CrPAT (Q1 FY27): ₹0.76 CrYoY Revenue Growth: -8.2%YoY PAT Growth: +13.4%Promoter Holding (Total): 36.44%Finance Costs (Q1): ₹2.42 Lakhs
📅 Short termThe stock may remain range-bound as the market balances the revenue contraction against the improved profitability and promoter buying.
📈 Long termThe company's high ROCE (23.3%) and low debt-to-equity (0.15) provide a stable foundation, but long-term value creation depends on scaling its medical equipment revenue beyond the current ₹22 Cr TTM level.
⚠ Risk flags
- Revenue contraction on both YoY and QoQ basis
- Small scale of operations (Micro-cap risk)
- Promoter pledge remains at 3.44% of total capital
Key Highlights
Revenue from operations decreased 8.2% YoY to ₹4.90 Cr from ₹5.34 Cr in Jun 2025.
Net Profit (PAT) increased 13.4% YoY to ₹0.76 Cr, up from ₹0.67 Cr in the year-ago period.
Finance costs saw a sharp reduction of 78.7% YoY, falling to ₹2.42 Lakhs from ₹11.38 Lakhs.
Promoter non-encumbered holding increased to 33.00% from 28.26% in the previous quarter.
Total expenses were contained at ₹3.90 Cr versus ₹4.47 Cr in Q1 FY26, a 12.7% reduction.
👀 What to Watch
Investors should monitor the 'Life Saving Devices' segment for signs of revenue recovery and track the impact of the increased promoter stake on corporate governance and growth strategy.
